Abstract

Objectives

The aim was to determine the direct impact of the COVID-19 pandemic on Spain’s health budget.

Methods

Budget impact analyses based on retrospective data from patients with suspected severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) admitted to a Spanish hospital between February 26 and May 21, 2020. Direct medical costs from the perspective of the hospital were calculated. We analyzed diagnostic tests, drugs, medical and nursing care, and isolation ward and ICU stays for three cohorts: patients seen in the emergency room only, hospitalized patients who tested positive for SARS-CoV-2, and patients who tested negative.

Results

The impact on the hospital’s budget for the 3 months was calculated at €15,633,180, 97.4% of which was related to health care and hospitalization. ICU stays accounted for 5.3% of the total costs. The mean cost per patient was €10,744. The main costs were staffing costs (10,131 to 11,357 €/patient for physicians and 10,274 to 11,215 €/patient for nurses). Scenario analysis showed that the range of hospital expenditure was between €14,693,256 and €16,524,924. The median impact of the pandemic on the Spanish health budget in the sensitivity analysis using bootstrapped individual data was €9357 million (interquartile range [IQR], 9071 to 9689) for the conservative scenario (113,588 hospital admissions and 11,664 ICU admissions) and €10,385 million (IQR, 110,030 to 10,758) for the worst-case scenario (including suspected cases).

Conclusion

The impact of COVID-19 on the Spanish public health budget (12.3% of total public health expenditure) is greater than multiple sclerosis, cancer and diabetes cost.

Details

Title
Hospitalization budget impact during the COVID-19 pandemic in Spain
Author
Carrera-Hueso, F J 1   VIAFID ORCID Logo  ; Álvarez-Arroyo, L 2   VIAFID ORCID Logo  ; Poquet-Jornet, J E 3   VIAFID ORCID Logo  ; Vázquez-Ferreiro, P 4   VIAFID ORCID Logo  ; Martínez-Gonzalbez, R 5   VIAFID ORCID Logo  ; El-Qutob, D 6   VIAFID ORCID Logo  ; Ramón-Barrios, M A 7   VIAFID ORCID Logo  ; Martínez-Martínez, F 8 ; Poveda-Andrés, J L 9 ; Crespo-Palomo, C 10 

 University Hospital La Plana, Pharmacy Service, Castellón, Spain 
 University Hospital La Plana, Pharmacy Service, Castellón, Spain; Pharmacy Doctoral Program at University of Granada, Granada, Spain (GRID:grid.4489.1) (ISNI:0000000121678994) 
 Hospital de Denia (Marina Salud), Pharmacy Service, Denia (Alicante), Spain (GRID:grid.4489.1) 
 Hospital Virxe da Xunqueira, Ophtalmology Department, Cee (A Coruña), Spain (GRID:grid.4489.1) 
 University Hospital La Plana, Informatics and computer Service, Villarreal (Castelló), Spain (GRID:grid.4489.1) 
 University Hospital La Plana, Allergy Service, Villarreal (Castelló), Spain (GRID:grid.4489.1) 
 University Hospital Doctor Peset, Internal Medicine Unit, Valencia, Spain (GRID:grid.411289.7) (ISNI:0000 0004 1770 9825) 
 University of Granada, Grupo Investigación de Atención Farmacéutica, Pharmacy and Pharmaceutical Technology Department, Granada, Spain (GRID:grid.4489.1) (ISNI:0000000121678994) 
 Hospital Universitari i Politecnic La Fe, Pharmacy Department, Valencia, Spain (GRID:grid.84393.35) (ISNI:0000 0001 0360 9602) 
10  University of Barcelona, Department G.M. statistics, Barcelona, Spain (GRID:grid.5841.8) (ISNI:0000 0004 1937 0247); Axentiva Solutions, Barcelona, Spain (GRID:grid.5841.8) 
Publication year
2021
Publication date
Dec 2021
Publisher
Springer Nature B.V.
e-ISSN
21911991
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2592769039
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.